Basilea Pharmaceutica Ltd a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.
- Read more about Basilea reports preclinical data on oncology drug candidates BAL0891
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/basilea-reports-preclinical-data-on-oncology-drug-candidates-bal0891
No comments:
Post a Comment